Eyestem Research Pvt Ltd announced positive results from its phase 1/2 trial ( NCT06394232) evaluating its investigational ...

Average improvement of 14.9 letters in visual acuity reported in the first six patients over a four-six month follow-up. Signs of disease reversal observed in some patients. Dr Jogin Desai, Founder ...

Eyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy ...

A cell-based subretinal implant shows promise in the treatment of geographic atrophy, achieving the unprecedented milestone ...

Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot ...

The cornea, lens and retina were removed from the eye ball, and four radial cuts were made on the isolated eyecups. The RPE-eyecups were flat mounted and then blocked with Blocking one histo (Nacalai ...

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and often leads to infant mortality In a breakthrough for Spinal Muscular ...

In what could be promising news for patients battling spinal muscular atrophy (SMA), the Delhi High Court has refused to allow a suit by Swiss pharma giant Roche seeking to restrain Indian drugmaker ...

an oral medicine for Spinal Muscular Atrophy (SMA). Loading content, please wait ...